Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07288177 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
A Phase 2 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Genmab.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 2
- Study locations
NCT07288177 is a Phase 2 study of Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by Genmab. The registered enrollment target is 240 participants, below the 285-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (16% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07288177, a Phase 2 study of Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by Genmab.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo. The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.
Conditions Studied
Interventions
- DRUG Rina-S
Study Locations (2)
Virginia
- Virginia Cancer Specialists - Fairfax
Minami Ward
- Japan Community Health Care Organization Chukyo Hospital - Nagoya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2028-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07288177
The ClinicalTrials.gov registry entry for NCT07288177 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (16% lower). The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which Rina-S is the first listed.
NCT07288177 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Virginia, Minami Ward.
Frequently Asked Questions
What is clinical trial NCT07288177 about?
NCT07288177 is a clinical study titled "Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer". This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active dr...
What is the current status of trial NCT07288177?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2026-01-30. Estimated completion is 2028-11-22.
What conditions does trial NCT07288177 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT07288177?
The interventions under investigation include: Rina-S (DRUG).
Who is sponsoring clinical trial NCT07288177?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07288177 being conducted?
This trial has 2 study locations across Virginia, Minami Ward. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
RECRUITING · Phase 2
-
Pembrolizumab for Advanced NSCLC and PS 2-3
RECRUITING · Phase 2
-
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
ACTIVE NOT RECRUITING · Phase 2
-
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.